TheraRadar
Clinical-Stage Companies / Shanghai Pharmaceuticals Holding

Shanghai Pharmaceuticals Holding

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 3/2/2025

30
Total Trials
3
Phase 3
18
Phase 2
10
Recruiting
243
Score

Pipeline by Phase

Phase 3
3
Phase 2
18
Phase 1
18

Therapeutic Focus

Advanced Solid Tumors Hypertension Locally Advanced or Metastatic Breast Cancer Advanced Solid Tumor Sarcoma, Ewing

Clinical Trials (30)

NCT05359068 Phase 3 COMPLETED

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Started: 6/10/2021

NCT05860465 Phase 2 RECRUITING

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Started: 9/8/2023

NCT06434597 Phase 2 RECRUITING

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Started: 7/17/2024

NCT05744687 Phase 2 RECRUITING

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Started: 4/24/2023

NCT05872347 Phase 2 RECRUITING

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Started: 9/19/2023

NCT05686642 Phase 2 RECRUITING

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Started: 4/6/2023

NCT05046314 Phase 2 COMPLETED

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Started: 3/12/2024

NCT05770609 Phase 2 COMPLETED

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Started: 6/19/2023

NCT05593575 Phase 2 COMPLETED

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Started: 3/22/2023

NCT04084444 Phase 2 COMPLETED

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Started: 12/25/2019

NCT03756103 Phase 2 COMPLETED

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

Started: 1/11/2019

NCT02201043 Phase 2 COMPLETED

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Started: 2/1/2013

NCT06214156 Phase 1 RECRUITING

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Started: 1/26/2024

NCT05944224 Phase 1 RECRUITING

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Started: 10/17/2023

NCT06487455 Phase 1 RECRUITING

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

Started: 8/6/2024

NCT06839131 Phase 1 RECRUITING

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

Started: 3/2/2025

NCT06214143 Phase 1 RECRUITING

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Started: 1/11/2024

NCT05088070 Phase 1 COMPLETED

Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors

Started: 7/2/2020

NCT05905614 Phase 1 COMPLETED

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Started: 11/3/2020

NCT06372223 Phase 1 COMPLETED

A Food Effect Study of SPH5030 Tablets.

Started: 3/4/2024

NCT03953833 Phase 1 COMPLETED

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

Started: 4/1/2019

NCT04382352 Phase 1 COMPLETED

B002 in Patients With HER2-positive Breast Cancer

Started: 5/28/2019

NCT05593562 Phase 1 COMPLETED

Study on Human Mass Balance of SPH3127 Tablets

Started: 10/16/2022

NCT03128138 Phase 1 COMPLETED

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

Started: 12/1/2016

NCT05359055 Phase 1 COMPLETED

Drug-drug Interaction Study of SPH3127

Started: 12/13/2021

NCT03332121 Phase 1 COMPLETED

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

Started: 3/22/2018

NCT03255993 Phase 1 COMPLETED

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Started: 10/23/2017

NCT03249753 Phase 1 COMPLETED

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

Started: 9/23/2017

NCT03231475 Phase 1 WITHDRAWN

Phase I Study of SPH1188-11 in NSCLC

Started: 7/21/2017

NCT02202395 Phase 1 COMPLETED

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Started: 6/1/2014

Drug Candidates

TK216+Vincristin T3011 SPH4336 Tablets SPH4336 Tablets Placebo SPH4336 Cadonilimab SPH3127 Tablets with Dose A SPH3127 Tablets with Dose B SPH3127 Tablets placebo SPH5030
Activity Status: Slowing
Last Trial Started: 3/2/2025
Last Trial Ended: 2/5/2025
Trials (12 months): 0
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.